CALCIUM Drug Patent Profile
When do Calcium patents expire, and when can generic versions of Calcium launch?
Calcium is a drug marketed by Adaptis, Amneal Pharms, Chartwell Rx, Cohance Lifesciences, Heritage Pharms Inc, Hikma, Invagen Pharms, Lotus Pharm Co Ltd, Lupin, Mpp Pharma, Chartwell Molecular, Padagis Us, Am Regent, Amneal, Intl Medication Sys, Medefil Inc, Pharmazone, Somerset, Square Pharms Plc, Hospira, Bausch, Abbott, Abraxis Pharm, Lilly, B Braun Medical, Caplin, Fresenius Kabi Usa, Hq Spclt Pharma, Nivagen, Cipla, Milla Pharms, and Sagent. and is included in thirty-eight NDAs. There are two patents protecting this drug.
The generic ingredient in CALCIUM is calcium gluconate. There are five drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the calcium gluconate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Calcium
A generic version of CALCIUM was approved as calcium gluconate by FRESENIUS KABI USA on June 15th, 2017.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for CALCIUM?
- What are the global sales for CALCIUM?
- What is Average Wholesale Price for CALCIUM?
Summary for CALCIUM
| US Patents: | 0 |
| Applicants: | 32 |
| NDAs: | 38 |
| Drug Prices: | Drug price information for CALCIUM |
| Drug Sales Revenues: | Drug sales revenues for CALCIUM |
| DailyMed Link: | CALCIUM at DailyMed |
US Patents and Regulatory Information for CALCIUM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nivagen | CALCIUM GLUCONATE | calcium gluconate | SOLUTION;INTRAVENOUS | 213071-002 | Oct 19, 2023 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| B Braun Medical | CALCIUM GLUCONATE | calcium gluconate | SOLUTION;INTRAVENOUS | 216541-001 | Aug 21, 2023 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Fresenius Kabi Usa | CALCIUM GLUCONATE IN SODIUM CHLORIDE | calcium gluconate | SOLUTION;INTRAVENOUS | 208418-004 | Jun 17, 2021 | DISCN | Yes | No | 10,130,646 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Sagent | CALCIUM GLUCONATE IN SODIUM CHLORIDE | calcium gluconate | SOLUTION;INTRAVENOUS | 219619-002 | Dec 30, 2025 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |



